Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838501 | 0.89 | WNT1 (0.43) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13838504 | 0.87 | CSNK1D (0.42) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13838352 | 0.86 | WNT1 (0.43) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13838453 | 0.81 | IL2 (0.50) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13838384 | 0.79 | IL2 (0.43) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13838315 | 0.79 | IL2 (0.42) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13838429 | 0.75 | KLRK1 (0.37) | ABCB1ABCC1WNT3ANTRK1TRPV1 | |
| SCHEMBL13838348 | 0.75 | ABL1 (0.40) | CSNK1DCSNK1EABCB1ABCC1ABL1 | |
| SCHEMBL13838578 | 0.71 | DYRK1A (0.52) | CSNK1DCSNK1EWNT1GSK3BDYRK1A | |
| SCHEMBL13730219 | 0.70 | ABL1 (0.43) | ABCB1ABCC1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | claimed |
| US-10399967-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2019-09-03 | — | — | US | disclosed |
| US-10399967-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2019-09-03 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2704701-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | CSNK1D 3201/4885CSNK1E 2697/4885WNT1 1992/4885 |
| US-10399967-B2 | Compounds for inflammation and immune-related uses | CXCL8, CCR1, CCR8 | CSNK1D 3201/4885CSNK1E 2697/4885WNT1 1992/4885 |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | CSNK1D 3201/4885CSNK1E 2697/4885WNT1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.